ATE554775T1 - Phospholipid-zusammensetzungen und ihre verwendungen - Google Patents

Phospholipid-zusammensetzungen und ihre verwendungen

Info

Publication number: ATE554775T1
Authority: AT; Austria
Prior art keywords: lipids; lrh; administration; blood glucose; glucose levels
Prior art date: 2007-11-16

Application number

AT08852865T

Other languages

English (en)

Inventor

David Moore

Jae Lee

Original Assignee

Baylor College Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-16

Filing date

2008-11-17

Publication date

2012-05-15

2008-11-17 Application filed by Baylor College Medicine filed Critical Baylor College Medicine

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE554775T1 publication Critical patent/ATE554775T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
150000003904 phospholipids Chemical class 0.000 title abstract 2
150000002632 lipids Chemical class 0.000 abstract 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 abstract 2
101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 abstract 2
239000008280 blood Substances 0.000 abstract 2
210000004369 blood Anatomy 0.000 abstract 2
239000008103 glucose Substances 0.000 abstract 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT08852865T 2007-11-16 2008-11-17 Phospholipid-zusammensetzungen und ihre verwendungen ATE554775T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98850507P	2007-11-16	2007-11-16
PCT/US2008/012846 WO2009067182A2 (en)	2007-11-16	2008-11-17	Phospholipid compositions and uses thereof

Publications (1)

Publication Number	Publication Date
ATE554775T1 true ATE554775T1 (de)	2012-05-15

Family

ID=40668049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08852865T ATE554775T1 (de)	2007-11-16	2008-11-17	Phospholipid-zusammensetzungen und ihre verwendungen

Country Status (7)

Country	Link
US (1)	US8410085B2 (de)
EP (1)	EP2219652B1 (de)
AT (1)	ATE554775T1 (de)
AU (1)	AU2008326800A1 (de)
CA (1)	CA2705530A1 (de)
DK (1)	DK2219652T3 (de)
WO (1)	WO2009067182A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0915523D0 (en)	2009-09-07	2009-10-07	Genome Res Ltd	Cells and methods for obtaining them
US20130210143A1 (en) *	2010-05-20	2013-08-15	Fundacion Publica Andaluza Progreso Y Salud	Novel methods for preventing or treating diabetes
US9512406B2 (en)	2013-12-20	2016-12-06	The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone	Generating hepatocytes
KR20180116275A (ko)	2016-02-22	2018-10-24	노파르티스 아게	Fxr 효능제를 사용하는 방법
KR101865562B1 (ko) *	2017-11-03	2018-06-08	주식회사 펜믹스	포스포콜린 유도체를 포함하는 지방분해 조성물
CN112533494A (zh) *	2018-06-22	2021-03-19	方塔拉合作集团有限公司	使用极性脂质治疗或预防妊娠期糖尿病
CN115364111B (zh) *	2021-05-17	2024-04-02	中国医学科学院基础医学研究所	甘油磷脂类化合物在治疗肿瘤中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5910304A (en)	1982-12-13	1999-06-08	Texas A&M University System	Low-dose oral administration of interferons
CA1320905C (en)	1986-11-06	1993-08-03	Joseph M. Cummins	Treatment of immuno-resistant disease
AU2738497A (en)	1996-04-24	1997-11-12	Brigham And Women's Hospital	Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6036949A (en)	1998-03-05	2000-03-14	Amarillo Biosciences, Inc.	Treatment of fibromyalgia with low doses of interferon
US6537806B1 (en)	1998-06-02	2003-03-25	University Of Washington	Compositions and methods for treating diabetes
US20030040505A1 (en)	2000-03-31	2003-02-27	The Regents Of The University Of California	Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
GB0014437D0 (en)	2000-06-14	2000-08-09	Porter William L	Immune response stimulation
WO2004039430A2 (en) *	2002-10-25	2004-05-13	Kurtz Seymour J	Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x
WO2004108140A1 (en)	2003-06-05	2004-12-16	Doosan Corporation	Composition for inhibiting differentiation or growth of fat cells
EP1680189A2 (de)	2003-11-05	2006-07-19	Schering Corporation	Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
WO2007065156A2 (en)	2005-12-02	2007-06-07	Nastech Pharmaceutical Company Inc.	Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
US20050255154A1 (en)	2004-05-11	2005-11-17	Lena Pereswetoff-Morath	Method and composition for treating rhinitis

2008
- 2008-11-17 CA CA2705530A patent/CA2705530A1/en not_active Abandoned
- 2008-11-17 AT AT08852865T patent/ATE554775T1/de active
- 2008-11-17 DK DK08852865.8T patent/DK2219652T3/da active
- 2008-11-17 WO PCT/US2008/012846 patent/WO2009067182A2/en not_active Ceased
- 2008-11-17 US US12/742,879 patent/US8410085B2/en not_active Expired - Fee Related
- 2008-11-17 AU AU2008326800A patent/AU2008326800A1/en not_active Abandoned
- 2008-11-17 EP EP08852865A patent/EP2219652B1/de not_active Not-in-force

Also Published As

Publication number	Publication date
EP2219652B1 (de)	2012-04-25
DK2219652T3 (da)	2012-08-06
WO2009067182A2 (en)	2009-05-28
EP2219652A2 (de)	2010-08-25
CA2705530A1 (en)	2009-05-28
US20100331281A1 (en)	2010-12-30
AU2008326800A1 (en)	2009-05-28
WO2009067182A3 (en)	2009-07-23
US8410085B2 (en)	2013-04-02
EP2219652A4 (de)	2010-11-10

Similar Documents

Publication	Publication Date	Title
ATE554775T1 (de)	2012-05-15	Phospholipid-zusammensetzungen und ihre verwendungen
Fine	2011	Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states
JP2007521835A5 (de)	2008-05-22
AU2018253580A1 (en)	2018-11-22	Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2010129138A3 (en)	2011-12-29	Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
Cavalcanti et al.	2014	Administration of reconstituted polyphenol oil bodies efficiently suppresses dendritic cell inflammatory pathways and acute intestinal inflammation
WO2011014661A3 (en)	2011-06-09	Liver x receptor agonists
BRPI0610321B8 (pt)	2021-05-25	imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
WO2010042886A3 (en)	2010-11-11	Pyrones for the treatment of metabolic disorders
PE20050255A1 (es)	2005-06-02	Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
TR201908522T4 (tr)	2019-07-22	Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
EA201400392A1 (ru)	2014-09-30	ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
JP2016517888A5 (de)	2017-06-15
HK1209633A1 (en)	2016-04-08	Compositions and methods for treating diabetes
IN2012MN02262A (de)	2015-06-12
EA201190209A1 (ru)	2012-04-30	Соединения для лечения метаболических расстройств
EA201190208A1 (ru)	2012-04-30	Соединения для лечения метаболических расстройств
DE602006012725D1 (de)	2010-04-15	Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201401231A1 (ru)	2015-08-31	Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
MX2015008837A (es)	2015-10-14	Composiciones parenterales estables de dnj.
JPWO2014115764A1 (ja)	2017-01-26	乳酸脱水素酵素阻害剤およびそれを含有する医薬品
WO2005113016A3 (en)	2006-05-04	Modulation of glucose-6-phosphatase translocase expression
GEP20125570B (en)	2012-07-10	Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
MX2009009171A (es)	2010-03-04	Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.
WO2007005502A3 (en)	2008-01-24	Methods and compositions for treating diseases targeting cdcp1